Elsevier MDL upgrades powerful MDL® Isentris® platform, integrating workflows and enhancing R&D productivity
Isentris 1.4 streamlines drug discovery and development process for scientists
San Leandro, CA, December 1, 2005 - Elsevier MDL, the leading informatics, database and workflow solution provider for life sciences R&D, has released an upgrade to the new-generation MDL® Isentris® informatics platform. The Isentris 1.4 release improves researchers’ ability to collate and manage data within scientific workflows and to make successful decisions based on that data, providing the foundation for improved research productivity.
“Isentris 1.4 enhances the productivity and efficiency of scientists by making it easier for them to access complex data from multiple sources along with the appropriate visualization and analysis tools,” said Vikki Rehn, Senior Vice President, Framework Business Group, Elsevier MDL. “By enabling scientists to easily access and understand the data that is generated throughout the entire drug discovery and development process, Isentris 1.4 enables R&D teams to rapidly make informed, successful decisions.”
Isentris supports a cohesive desktop research environment by rapidly integrating specialized in-house and third-party applications. A growing community of companies, including Spotfire, InforSense and Tripos, in the MDL® Isentris® Alliance is utilizing the open technology framework to provide research organizations with integrated solutions that can deliver significant cost benefits and reduced time-to-market.
Elsevier MDL is building key new procurement, inventory, chemical registration and data-access solutions, including an electronic notebook and the popular DiscoveryGate® content platform, on Isentris technology.
Highlights of the MDL Isentris 1.4 release include:
• Simplified data access: Information can be centralized and automatically focused to address researchers’ questions, avoiding information overload and project delays.
• Re-usable workflows: Researchers can capture their questions and decision-making processes. These records can be saved, shared with colleagues, compared and re-run to improve productivity.
• Improved workflows: Daily and weekly research workflows can be quickly configured to enable researchers’ data to follow their data collation and decision-making needs.
• Enriched data: Research information viewed in Isentris applications can be enriched from diverse sources, such as Web services or third-party calculators.
Formally introduced in December 2004, the Isentris platform provides significant advances over proven MDL ISIS cheminformatics technology. Components of the Isentris technology are already widely used by the majority of leading pharmaceutical companies around the world. The complete Isentris platform now offers research organizations a clear path to improved R&D productivity and higher return on investment. For more information about Isentris and Isentris-based workflow applications, visit www.mdl.com.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
Dr. Phil McHale
VP, Market and Corporate Communications
(510) 357-2222 ext. 3541
MDL and Isentris are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.